Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg, Granted competitive generic therapy designation and is eligible for 180 days of CGT exclusivity.
In: ENP Newswire, 2021-03-24
Zeitungsartikel
Zugriff:
Titel: |
Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg, Granted competitive generic therapy designation and is eligible for 180 days of CGT exclusivity.
|
---|---|
Zeitschrift: | ENP Newswire, 2021-03-24 |
Veröffentlichung: | 2021 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|